Aslan Pharmaceuticals presents data on eblasakimab as ATS conference

ASLAN Pharmaceuticals announced the late-breaking poster presentation of translational data from head-to-head studies of eblasakimab and dupilumab in human healthy and COPD-derived lung tissue models at the American Thoracic Society, ATS, International Conference 2024 in San Diego, California. Eblasakimab Significantly Alleviates IL-4 and IL-13 Induced Bronchial Airway Constriction in COPD-Derived Lung Slices: PCLS from a 66-year-old male with no known history of lung diseases and a 67-year-old female with COPD were used to test constriction and dilation responses to different treatment conditions including IL-4, IL-13, methacholine, formoterol, and a range of concentrations of dupilumab and eblasakimab. In both healthy and COPD-derived lung tissues, eblasakimab significantly reduced IL-4- and IL-13-induced bronchial airway constriction. In IL-4 and IL-13 pre-treated healthy lung tissues, eblasakimab further restored formoterol-induced airway dilation, significantly better than dupilumab at the lower concentration, and improved methacholine-induced constriction. The results suggest eblasakimab may provide a therapeutic benefit in reducing IL-4- and IL-13-induced airway hyperresponsiveness and that eblasakimab may provide relief in situations of acute airway constriction. In COPD PCLS, eblasakimab showed significant improvement across all measured bronchial outcomes whereas dupilumab, tested at the same concentrations, did not achieve statistical significance relative to placebo for all measures. The results support further investigation of eblasakimab as a therapeutic option for COPD with potentially more effective blockade of Type-2 mediated effects in lung tissue and improvement in bronchoconstriction.